- Trials with a EudraCT protocol (286)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
286 result(s) found for: Binding Potential.
Displaying page 1 of 15.
EudraCT Number: 2019-002232-82 | Sponsor Protocol Number: KIH18001 | Start Date*: 2019-07-25 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Downstream targets of SSRI effect in treatment of Major Depressive Disorder | ||
Medical condition: Major depressive disorder (MDD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001008-37 | Sponsor Protocol Number: Bab1 | Start Date*: 2005-11-01 |
Sponsor Name:Sahlgrenska University Hospital | ||
Full Title: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003714-24 | Sponsor Protocol Number: 0515 | Start Date*: 2016-03-29 |
Sponsor Name:Biomedizinische Forschung und Bio-Produkte AG | ||
Full Title: Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults | ||
Medical condition: Healthy adults | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004979-19 | Sponsor Protocol Number: EK Reg.-Nr. 040-2007 | Start Date*: 2009-01-08 |
Sponsor Name:University of Leipzig | ||
Full Title: In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET) | ||
Medical condition: To test a diagnostic imaging tool for specifically assessing the nicotinic acetylcholine receptor in vivo in patients with neurodegenerative diseases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001993-52 | Sponsor Protocol Number: IMCOVAS | Start Date*: 2021-05-20 |
Sponsor Name:University of Antwerp | ||
Full Title: Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vacc... | ||
Medical condition: Coronavirus disease-19 (COVID-19) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003286-34 | Sponsor Protocol Number: CHUBX2017/22 | Start Date*: 2019-03-05 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: In vivo involvement of the cholinergic and dopaminergic systems in the pathophysiology of apathy. | ||||||||||||||||||
Medical condition: Apathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008238-35 | Sponsor Protocol Number: AMLSG11-08 | Start Date*: 2009-06-24 |
Sponsor Name:Universitätsklinikum Ulm | ||
Full Title: Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Co... | ||
Medical condition: Newly diagnosed core binding factor acute myeloid leukemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004448-37 | Sponsor Protocol Number: PET-CFS-1 | Start Date*: 2015-09-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Visualising neuroinflammation in chronic fatigue syndrome patients | ||
Medical condition: Chronic Fatigue Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003279-41 | Sponsor Protocol Number: PSY-NIL-0013 | Start Date*: 2023-03-31 |
Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy | ||
Full Title: Investigating N-methyl-d-aspartate (NMDA) receptor alterations in major depressive disorder by brain PET | ||
Medical condition: Major Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000040-30 | Sponsor Protocol Number: 202100912 | Start Date*: 2023-03-06 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: An open label pilot study of [18AlF]-Resca-IL2 (Interleukin-2 PET tracer) for positron emission tomography imaging in patients treated with immune checkpoint inhibitors. | ||
Medical condition: patients with stage IV non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), CSCC, urothelial cell cancer (UCC), and head and neck squamous cell carcinoma (HNSCC), eligible for ICI the... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003117-18 | Sponsor Protocol Number: AMLSG21-13 | Start Date*: 2014-07-14 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13 | ||
Medical condition: Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001545-20 | Sponsor Protocol Number: mRNA-1647-P104 | Start Date*: 2024-05-09 |
Sponsor Name:ModernaTX, Inc. | ||
Full Title: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age... | ||
Medical condition: Cytomegalovirus infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-003280-38 | Sponsor Protocol Number: PSY-NIL-0006 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response | |||||||||||||
Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001411-82 | Sponsor Protocol Number: HIPRA-HH-1 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:LABORATORIOS HIPRA, S.A. | |||||||||||||
Full Title: A phase I/IIa study to evaluate safety and immunogenicity of recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers. | |||||||||||||
Medical condition: SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007394-22 | Sponsor Protocol Number: PK11195 | Start Date*: 2008-05-22 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000074-25 | Sponsor Protocol Number: HIPRA-HH-5 | Start Date*: 2022-02-01 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A PHASE III, OPEN LABEL TRIAL, SINGLE ARM, MULTI-CENTER, TRIAL TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION HETERODIMER CANDIDATE (PHH-1V) ... | |||||||||||||
Medical condition: SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000307-93 | Sponsor Protocol Number: CICL670F2105 | Start Date*: 2016-03-09 |
Sponsor Name:Novartis Pharmaceuticals Corporation | ||
Full Title: A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formu... | ||
Medical condition: Healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-002088-23 | Sponsor Protocol Number: DemiVac2021 | Start Date*: 2021-05-05 |
Sponsor Name:Sciensano | ||
Full Title: Covid-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population (REDU-VAC) | ||
Medical condition: Healthy persons from age 18 till age 56 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000795-19 | Sponsor Protocol Number: HIPRA-HH-10 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIME... | |||||||||||||
Medical condition: SARS-COV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004578-40 | Sponsor Protocol Number: SSAT066 | Start Date*: 2015-01-26 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal ... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.